Pharmaceutical circle five investment and financing mergers and acquisitions event | will completely change the industry pattern!

Pharmaceutical Network February 22 hearing just past the Year of the Rookie, many large pharmaceutical companies to accelerate the pace of expansion of the staking area of ​​the footsteps Next, the New World sector for many mergers and acquisitions occurred throughout the year investment and financing incidents were summed up, summed up the top five Mergers and acquisitions in the pharmaceutical industry events, take a look at these investment and financing mergers and acquisitions for the Chinese pharmaceutical industry will have an impact on how the future competitive landscape will evolve?

On January 31, 2018, Biotest, a German plasma manufacturer, announced that Corey Group from China had completed its acquisition and the underlying shares had been delivered to the relevant acquisition entity of Corey Group. Upon completion of the transaction, Corey The Group will have six blood products companies (Shanghai Lai Shi (002252), BPL and Biotest, etc.), the overall scale among the ranks of the world's blood products giant, a total of 120 pulp stations, ranking the world's third; the existing total capacity 4550 tons, under construction capacity of 1820 tons, a total of more than 6,000 tons, ranking No. 4 in the world; the total number of products reached 23, the world No. 1. So far, this much-anticipated medicine Circle blood products mergers and acquisitions finally completed the delivery, all the dust settles.

Comments:

This transaction was the most expensive M & A deal last year in the domestic medicine circle, helping Shanghai Lai Shi to enhance its strength and establish its domestic blood product giant enterprise Dominance mergers and acquisitions in recent years is also a major trend in the blood products industry, several major giants in China's blood products industry in addition to Hualan biological (002007) ten years there is no big move, the other several are in the stampede to speed up the action .

As the blood products industry has high manufacturing barriers and few enterprises, the demand has been growing. However, with the development of society and economy, the increase of the clinically applicable symptoms of the products, the increase of the population of the aging population and the increasing demand of the domestic blood products, Coupled with the new version of Medicines and Health Products in the blood reimbursement range contrarian surge, as well as blood products to limit the national conditions of imports is expected in the next few years, China's domestic blood products industry prospects.

Shanghai Lai Shi through successive mergers and acquisitions in recent years, coupled with its own strength, is expected to further lay the domestic blood products industry giant position in the future, and a series of large mergers and acquisitions also demonstrated its desire to dominate the ambitions of its market The status will be further enhanced, which may bring some influence on the other blood products giant Hualan.In addition, the domestic blood products industry is noteworthy star ST Biochemical (000403) was Zhejiang MinTiao successful offer, the controversy or control Its future performance has a certain impact.

On November 13, 2017, Fu Jen Pharmaceutical (600781) announced that it intends to issue shares and pay cash to buy Furen Pharmaceutical Group Co., Ltd. and other 14 counterparties together held a total of 100% Equity and to not more than 10 eligible specific non-public offering of shares to raise funds, the total amount of not more than 5.3 billion Funeral Pharmaceutical intends to Fu Jen Catholic University, Ping Jia Xin Yuan, Jin Cheng Henan medicine, million Jia Xin Wang, Ding Liang Kai Yao, Crete, Everest Cornerstone, Cornerstone, Jincheng Zhixin, East Datang, East Tuyao Yao, Peizi investment, the cornerstone of the sea, the cornerstone 14 Central and South Africa counterparts to issue shares And pay the cash to buy open medicine group equity, the trading price of 7.809 billion yuan.

Comments:

It is reported that Fu Jen Catholic medicine as early as 2015 has already begun to plan the acquisition of Kai Pharmaceutical Group, only two years after the successful conclusion of the acquisition, the Kai Pharmaceutical Group will make Fu Jen Catholic medicine in the chemical and pharmaceutical raw materials in the field of blank, And expand its scale of the field of proprietary Chinese medicines.And Furen Pharmaceutical's financial data in the relative ranking of the domestic pharmaceutical companies rely on, the acquisition of medicine, its total assets can reach 9.22 billion yuan, to further enhance the body size. , Fu Jen Pharmaceutical can become a large comprehensive medical listed company with business covering chemical, proprietary, API and biopharmaceuticals. The core high quality pharmaceutical assets of Fu Jen Group have been injected into listed companies and the pharmaceutical industry The issue of competition will be significantly reduced.

In recent years, due to regulatory touches and other factors, in the past, the brutal growth of proprietary Chinese medicine companies changed the environment, some traditional Chinese medicine companies began to get involved in the field of chemical and proprietary Chinese medicines, but the basic are minor hits. Pen big step-by-step transactions, from a single Chinese-funded enterprises to transition to a comprehensive enterprise, its success or not in the next few years, it is likely to many Chinese medicine enterprises in the future whether the transformation of the decision to some extent.

In March 2017, Yunnan Baiyao (000538) issued a tender offer stating that due to the mixed ownership reform by the controlling shareholder Baiyin Holdings, Xinhuadu (002264) acquired a 50% stake in Baiyao Holdings through capital increase and the shareholder structure of Baiyaku Holdings Changes.A month later, Yunnan Baiyao mixed change boots formally landed, Yunnan SASAC, Xinhuadu, Yuyue Medical (002223) held a 45% stake in Baiyao, 45% and 10% stake in Yunnan Baiyao Holdings Limited Executives are no longer retain the provincial state-owned enterprises leadership status and rank treatment, but by market-based approach to hiring, become a professional manager.

Comments:

It can be said that Yunnan SASAC has thoroughly carried out the reform on the reform of BBA, setting a sample for the reform of state-owned pharmaceutical enterprises. However, the tide of reform of state-owned pharmaceutical companies is hit, but the successful experience is still relatively small. How to deepen the reform, The system how to separate from the administrative system is still to be explored.The successful model of Yunnanbaiyao also provides experience for the state-owned enterprises that are about to enter the reform in the future Public information shows that the number of state-owned enterprises in the pharmaceutical industry is about 823, the scale of assets 172.8 billion yuan in the A-share listed pharmaceutical companies, there are 48 state-owned nature of the company.

In December 2017, Fosun Pharma (600196) announced that it planned to invest 330 million yuan to subscribe Fuxin Hailin new shares. Other investors include Chongqing Gotech, Shenzhen Gotech, Jiaxing Shen Trade, Joyful

Ascent, Green

Tomato, Komsomolsk-In-the-Middle, Yinxun and other seven foreign investors invested a total of 140 million U.S. dollars to subscribe to Fuhong Hanlin's new issue of 40.85 million shares, accounting for about 9.09% of the total number of shares. Medicine still holds about 62.44% stake in Fuhong Hanlin.

Comments:

Fuhong Hanlin is a pharmaceutical R & D and manufacturing company jointly established by Fosun Pharma and Hanlin Bio. The main directions are research and development and industrialization of monoclonal antibody bio-analogs, biologically modified drugs and monoclonal antibodies. At present, about 400 million accumulatively invested Yuan for the monoclonal antibody drug research and development.It also represents a trend of domestic pharmaceutical investment, preferring to enrich the product line and product realization strength of the enterprise, while the previously touted small growth companies, the theme of the concept of enterprise last year Has been a rare case of cold. 'Constant strong, value investing' concept will also become the theme of the financing community in the next few years.

The most concerned about the mergers and acquisitions outside the case: Ma, Wu Guangming, Yu Rong joint acquisition of Yum Healthcare

December 8, Wandong Medical (600055) issued a public notice to disclose the progress of the acquisition of Yum Healthcare to acquire the entire equity of Yum! Medical (excluding treasury shares) for 248 million euros (about 1.937 billion yuan) .The final share purchase price will be based on 2017 The actual net debt and net working capital balance of the audit was adjusted on December 31. In the current round of acquisition, Ma Yun's Yunfeng Fund led and subscribed 30.7% of the total investment, while Wu Guangming's diving technology held a 17.1% stake. Of Wudong Medical held 18.0%, Yuyao Shanghai Tianyi Industrial Holding 16.0%; Shanghai Free Trade Zone Tri-stage equity investment fund holding 12.6%.

Comments:

Big health The hot industry, has always attracted the attention of the capital outside the circle, and the investment in Ma, Wu Guangming, Yu Rong is undoubtedly a wise move. The tripartite alliance to jointly create a medical image of the Empire: the introduction of international high-end images Equipment, Wandong further optimize the product mix, to seize market share, leveraging the support of diving technology, the accumulation of big data; the United States of America Health (002044) Join Bringing the platform traffic; Ali system is to provide technical support in the imaging diagnosis, big data, AI, etc. to create cloud technology services to address the pain points of medical resources.